Multivariate analysis of recipient and donor CCR5 genotypes
| Outcome . | Recipient CCR5 genotype . | Donor CCR5 genotype . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% confidence interval . | P . | HR . | 95% confidence interval . | P . | |
| Overall survival | 1.28 | (1.038-1.587) | .021 | 0.85 | (0.694-1.040) | .114 |
| Disease-free survival | 1.36 | (1.098-1.684) | .005 | 0.80 | (0.651-0.973) | .026 |
| Relapse | 0.74 | (0.522-1.056) | .098 | 1.26 | (0.905-1.748) | .171 |
| Treatment-related mortality | 0.76 | (0.58-0.987) | .039 | 1.16 | (0.903-1.495) | .243 |
| Grade III-IV GVHD | 1.04 | (0.746-1.438) | .833 | 1.46 | (1.07-1.982) | .017 |
| Chronic GVHD | 1.00 | (0.784-1.283) | .982 | 1.00 | (0.772-1.307) | .976 |
| Outcome . | Recipient CCR5 genotype . | Donor CCR5 genotype . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% confidence interval . | P . | HR . | 95% confidence interval . | P . | |
| Overall survival | 1.28 | (1.038-1.587) | .021 | 0.85 | (0.694-1.040) | .114 |
| Disease-free survival | 1.36 | (1.098-1.684) | .005 | 0.80 | (0.651-0.973) | .026 |
| Relapse | 0.74 | (0.522-1.056) | .098 | 1.26 | (0.905-1.748) | .171 |
| Treatment-related mortality | 0.76 | (0.58-0.987) | .039 | 1.16 | (0.903-1.495) | .243 |
| Grade III-IV GVHD | 1.04 | (0.746-1.438) | .833 | 1.46 | (1.07-1.982) | .017 |
| Chronic GVHD | 1.00 | (0.784-1.283) | .982 | 1.00 | (0.772-1.307) | .976 |
Comparison for all categories is H1/H1 vs other. GVHD indicates graft-versus-host disease; and HR, hazard ratio.